CA3075649A1 - A novel small molecule compound - Google Patents

A novel small molecule compound Download PDF

Info

Publication number
CA3075649A1
CA3075649A1 CA3075649A CA3075649A CA3075649A1 CA 3075649 A1 CA3075649 A1 CA 3075649A1 CA 3075649 A CA3075649 A CA 3075649A CA 3075649 A CA3075649 A CA 3075649A CA 3075649 A1 CA3075649 A1 CA 3075649A1
Authority
CA
Canada
Prior art keywords
disease
cancer
cpt
mitochondrial
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3075649A
Other languages
English (en)
French (fr)
Inventor
Bingwei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerepeut LLC
Original Assignee
Cerepeut LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerepeut LLC filed Critical Cerepeut LLC
Publication of CA3075649A1 publication Critical patent/CA3075649A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3075649A 2017-09-13 2018-09-12 A novel small molecule compound Pending CA3075649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
CA3075649A1 true CA3075649A1 (en) 2019-03-21

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075649A Pending CA3075649A1 (en) 2017-09-13 2018-09-12 A novel small molecule compound

Country Status (9)

Country Link
US (3) US11186550B2 (https=)
EP (1) EP3681874B1 (https=)
JP (1) JP7170341B2 (https=)
KR (1) KR102644045B1 (https=)
CN (1) CN111372921B (https=)
AU (1) AU2018331371C1 (https=)
CA (1) CA3075649A1 (https=)
IL (1) IL273242B2 (https=)
WO (1) WO2019055528A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454514B2 (en) 2019-02-27 2025-10-28 Cerepeut, Inc. Quinazolinone compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368434B2 (en) 2002-06-27 2008-05-06 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of ALDH
WO2005051974A2 (en) 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
US8759097B2 (en) * 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN105008515A (zh) 2012-12-28 2015-10-28 小利兰·斯坦福大学托管委员会 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
US9730935B2 (en) * 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454514B2 (en) 2019-02-27 2025-10-28 Cerepeut, Inc. Quinazolinone compounds

Also Published As

Publication number Publication date
US11186550B2 (en) 2021-11-30
US11912669B2 (en) 2024-02-27
KR20200053560A (ko) 2020-05-18
US20220340534A1 (en) 2022-10-27
JP2020533399A (ja) 2020-11-19
IL273242B2 (en) 2023-08-01
AU2018331371A1 (en) 2020-04-02
AU2018331371C1 (en) 2024-05-09
CN111372921B (zh) 2023-12-01
US12404251B2 (en) 2025-09-02
IL273242A (en) 2020-04-30
KR102644045B1 (ko) 2024-03-05
IL273242B1 (en) 2023-04-01
JP7170341B2 (ja) 2022-11-14
EP3681874A1 (en) 2020-07-22
WO2019055528A1 (en) 2019-03-21
AU2018331371B2 (en) 2024-02-15
EP3681874B1 (en) 2022-04-06
EP3681874A4 (en) 2021-01-13
CN111372921A (zh) 2020-07-03
US20240246919A1 (en) 2024-07-25
US20200216400A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
US12404251B2 (en) Small molecule compound
JP2021527125A (ja) Ｓａｒｍ１阻害剤
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
CA3234750A1 (en) Modulators of sestrin-gator2 interaction and uses thereof
EP3129378B1 (en) Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
EP3493848B1 (en) Heterocyclic diamidines
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
US12454514B2 (en) Quinazolinone compounds
US20240382509A1 (en) Cannabinoids C- and O-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof
US20210308111A1 (en) Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
CN100415219C (zh) 取代的二环[3.3.1]壬烷-2,4,9三酮作为活性药物成分
KR20030085421A (ko) ｐ53 또는 ｐ21 유전자 변이에 의해 ｐ53 또는 ｐ21유전자 기능을 상실한 암의 치료를 위한 액틴 저해제를포함하는 약학 조성물
EP4238562B1 (en) Andrographolide derivative for use in the treatment of inflammatory diseases associated with a cytokine storm
HK40086108A (en) Modulators of sestrin-gator2 interaction and uses thereof
HK1251486B (en) Modulators of sestrin-gator2 interaction and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230907

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241017

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250702

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250811

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250915

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251119

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251119